eli lilly and company

Eli Lilly’s stock falls

Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.

YAHOO!Finance · 22h

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.

Investopedia on MSN · 15h

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.

Eli Lilly acquires cancer program from Scorpion Therapeutics

Reuters · 1d

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

The Wall Street Journal on MSN · 1d

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

MT Newswires on MSN · 1d

Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion

Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront payment and subsequent amounts that Scorpion's shareholders would receive as certain regulatory and sales milestones are achieved.

45m

Has Eli Lilly Stock Peaked?

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

Pharmaceutical Technology2h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

1hon MSN

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, BlackRock, Eli Lilly, D-Wave Quantum, and More

Stock futures rose Wednesday ahead of data on U.S. consumer price inflation and as some of the nation’s largest banks began ...

10hon MSN

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

14h

Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

pharmaphorum1h

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

20h

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

20h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly’s stock falls

Eli Lilly acquires cancer program from Scorpion Therapeutics

Related topics